维生素K依赖的抗凝固因子,蛋白S,调节血管透性
Aurélie Joussaume1, Chryso Kanthou2, Olivier E Pardo3
1Université de Poitiers, CHU de Poitiers, ProDiCeT, UR 24144 Poitiers, France.
Current issues in molecular biology
|April 26, 2024
概括
蛋白S (PROS1) 通过激活特定的信号通路,增加了血管的通透性. 这种抗凝血因子通过MERTK和TYRO3受体影响内皮细胞和血管完整性.
科学领域:
- 血管生物学 血管生物学
- 内分泌学 在内分泌学.
- 细胞信号传递 细胞信号传递
背景情况:
- 蛋白S (PROS1) 是一种依赖维生素K的抗凝剂.
- PROS1作为TYRO3,AXL和MERTK (TAM) 氨酸激酶受体的激素作用.
- 内皮细胞产生PROS1并表达TAM受体,但PROS1对血管的影响在很大程度上是未知的.
研究的目的:
- 研究PROS1对内皮细胞透性和信号传导的影响.
- 确定涉及PROS1介导血管变化的特定信号通路和受体.
主要方法:
- 透井透性试验被用来测量内皮细胞的透性.
- 西方涂抹和免疫染色分析了蛋白质酸化和分布.
- 使用对TAM受体的中和抗体来确定受体的参与.
主要成果:
- PROS1显著增加了基底和VEGFA诱导的内皮细胞透性.
- PROS1激活了p38的MAPK,Rho/ROCK,c-Src和PAK-1信号通路.这些信号通路可以通过PROS1来传递.
- PROS1诱导了血管内皮卡德林 (VEC) 分布,酸化和裂变的变化.
- 通过MERTK和TYRO3受体调解PROS1诱导的VEC,c-Src和肌光链酸化.
结论:
- PROS1作为一种内源性血管透因子.
- PROS1信号包括c-Src/VEC和Rho/ROCK/MLC通路的激活.
- MERTK和TYRO3受体是PROS1对血管透性的影响的关键媒介.
更多相关视频
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
687
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
687
Clot Retraction and Fibrinolysis
5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K
Extrinsic and Intrinsic Pathways of Hemostasis
7.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.3K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Coagulation
6.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.4K


